FDA compounding enforcement update — June 2026 guidance document
Pinned because it affects plans people have already made, not because it is dramatic. Everything below is what is confirmed as of today.
This post is the record, and it will be edited as things change — with the change noted rather than substituted. If you have something firmer than what is here, a document or a date or a first-hand account, post it and it goes in with credit.
Read it this way:
- What is stated is confirmed; what is uncertain is marked as uncertain
- Anything time-sensitive is worth verifying yourself before you act on it
- The replies below carry the corrections, so read them before asking
Nothing here is advice about your situation, and the situation is still moving.
RegAffairsDC said:FDA compounding enforcement update — June 2026 guidance document Pinned because it affects plans people have already made, not because it is dramatic.
No disagreement with RegAffairsDC. One condition attached. Worth adding the genuine exception, because it is real and narrow: a change made for an identified patient where the prescriber determines it produces a significant clinical difference for that patient. A grid of fixed doses offered to everybody is not that, whatever the intake form says.
RegAffairsDC said:FDA compounding enforcement update — June 2026 guidance document Pinned because it affects plans people have already made, not because it is dramatic.
I read this differently from RegAffairsDC, on substance rather than tone. A research-chemical supplier selling lyophilised powder labelled research use only is not compounding and is not claiming to. It is a different legal universe with no pharmacy oversight, no patient relationship and no content guarantee, and conflating the two in these threads helps nobody.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsThis one has a reasonably settled answer, so here it is. Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists. For 503B the shortage clause was the only route to these molecules, so that route shut completely. A 503A pharmacy can still argue a doorway via "component of an approved drug" — but only for the substance in the form present in the approved product, which is exactly where the base-versus-salt argument lives, and it does nothing about the copy restriction, which came back into force on resolution.
Dr.LipidDallas said:Worth adding the genuine exception, because it is real and narrow: a change made for an identified patient where the prescriber determines it produces…
Can confirm the pattern Dr.LipidDallas describes. The shortage clause is the answer to the second question and it is a subtraction rather than an addition. Both exemptions forbid compounding something that is essentially a copy of a commercially available approved product. A product FDA has listed as in shortage is not treated as commercially available, so listing removed the objection that otherwise blocked compounding. It never created a permission; it withdrew a prohibition, which is why it evaporated the moment the supply fact changed.